Toolkit/cell-free chromatin immunoprecipitation

cell-free chromatin immunoprecipitation

Assay Method·Research·Since 2021

Also known as: cfChIP

Taxonomy: Technique Branch / Method. Workflows sit above the mechanism and technique branches rather than replacing them.

Summary

Cell-free chromatin immunoprecipitation (cfChIP) is an assay method that immunoprecipitates histone mark-associated cell-free chromatin from blood plasma. In the cited study, cfChIP targeting H3K36me3-associated cfDNA was used with droplet digital PCR to infer transcriptional activity of specific genes, including EGFR, in the cells that released the cfDNA.

Usefulness & Problems

Why this is useful

cfChIP is useful for extracting transcription-state information from plasma-derived cell-free DNA rather than measuring only sequence variation. The cited work indicates that H3K36me3-associated cfDNA can report whether a particular gene is being transcribed in the source cells and can distinguish enrichment of mutant versus wild-type EGFR fragments in NSCLC plasma.

Problem solved

This method addresses the problem that conventional cfDNA analyses primarily detect genotype but do not directly indicate whether a specific gene is actively transcribed in the cells shedding the DNA. The reported cfChIP approach uses a transcription-associated histone mark, H3K36me3, to infer gene expression status from circulating chromatin fragments.

Problem links

Fundamental Biomolecular Actors in Cells Remain Largely Invisible

Gap mapView gap

cfChIP provides a way to infer otherwise hidden transcriptional activity from histone mark-associated cell-free chromatin. It is actionable and measurement-oriented, but it addresses a narrow extracellular proxy of gene activity rather than direct, multiplex single-cell measurement of proteins, lipids, or metabolites.

Taxonomy & Function

Implementation Constraints

cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: sensor

The reported implementation uses blood plasma as the input material and immunoprecipitation of H3K36me3-associated cell-free chromatin. Detection of allele-specific enrichment was performed by droplet digital PCR comparing EGFR-L858R and EGFR-WT fragments in NSCLC patient samples.

The supplied evidence is limited to a single 2021 study focused on EGFR in non-small-cell lung cancer plasma samples. No broader performance metrics, sensitivity limits, antibody requirements, or validation across additional histone marks, genes, or disease contexts are provided in the evidence.

Validation

Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication

Supporting Sources

Ranked Claims

Claim 1assay capabilitysupports2021Source 1needs review

cfChIP of H3K36me3-associated cfDNA has the potential to delineate whether transcription of a particular gene is occurring in the cells from which its cfDNA originates.

Claim 2assay capabilitysupports2021Source 1needs review

cfChIP of H3K36me3-associated cfDNA has the potential to delineate whether transcription of a particular gene is occurring in the cells from which its cfDNA originates.

Claim 3assay capabilitysupports2021Source 1needs review

cfChIP of H3K36me3-associated cfDNA has the potential to delineate whether transcription of a particular gene is occurring in the cells from which its cfDNA originates.

Claim 4assay capabilitysupports2021Source 1needs review

cfChIP of H3K36me3-associated cfDNA has the potential to delineate whether transcription of a particular gene is occurring in the cells from which its cfDNA originates.

Claim 5assay capabilitysupports2021Source 1needs review

cfChIP of H3K36me3-associated cfDNA has the potential to delineate whether transcription of a particular gene is occurring in the cells from which its cfDNA originates.

Claim 6assay capabilitysupports2021Source 1needs review

cfChIP of H3K36me3-associated cfDNA has the potential to delineate whether transcription of a particular gene is occurring in the cells from which its cfDNA originates.

Claim 7assay capabilitysupports2021Source 1needs review

cfChIP of H3K36me3-associated cfDNA has the potential to delineate whether transcription of a particular gene is occurring in the cells from which its cfDNA originates.

Claim 8enrichment resultsupports2021Source 1needs review

In blood plasma from NSCLC patients harboring EGFR-L858R, H3K36me3 cfChIP followed by ddPCR revealed significantly higher enrichment of EGFR-L858R fragments than EGFR-WT fragments.

Claim 9enrichment resultsupports2021Source 1needs review

In blood plasma from NSCLC patients harboring EGFR-L858R, H3K36me3 cfChIP followed by ddPCR revealed significantly higher enrichment of EGFR-L858R fragments than EGFR-WT fragments.

Claim 10enrichment resultsupports2021Source 1needs review

In blood plasma from NSCLC patients harboring EGFR-L858R, H3K36me3 cfChIP followed by ddPCR revealed significantly higher enrichment of EGFR-L858R fragments than EGFR-WT fragments.

Claim 11enrichment resultsupports2021Source 1needs review

In blood plasma from NSCLC patients harboring EGFR-L858R, H3K36me3 cfChIP followed by ddPCR revealed significantly higher enrichment of EGFR-L858R fragments than EGFR-WT fragments.

Claim 12enrichment resultsupports2021Source 1needs review

In blood plasma from NSCLC patients harboring EGFR-L858R, H3K36me3 cfChIP followed by ddPCR revealed significantly higher enrichment of EGFR-L858R fragments than EGFR-WT fragments.

Claim 13enrichment resultsupports2021Source 1needs review

In blood plasma from NSCLC patients harboring EGFR-L858R, H3K36me3 cfChIP followed by ddPCR revealed significantly higher enrichment of EGFR-L858R fragments than EGFR-WT fragments.

Claim 14enrichment resultsupports2021Source 1needs review

In blood plasma from NSCLC patients harboring EGFR-L858R, H3K36me3 cfChIP followed by ddPCR revealed significantly higher enrichment of EGFR-L858R fragments than EGFR-WT fragments.

Claim 15proof of principlesupports2021Source 1needs review

This study provides proof of principle that cfChIP can be used to identify tumor-specific transcriptional activity of mutated alleles.

Claim 16proof of principlesupports2021Source 1needs review

This study provides proof of principle that cfChIP can be used to identify tumor-specific transcriptional activity of mutated alleles.

Claim 17proof of principlesupports2021Source 1needs review

This study provides proof of principle that cfChIP can be used to identify tumor-specific transcriptional activity of mutated alleles.

Claim 18proof of principlesupports2021Source 1needs review

This study provides proof of principle that cfChIP can be used to identify tumor-specific transcriptional activity of mutated alleles.

Claim 19proof of principlesupports2021Source 1needs review

This study provides proof of principle that cfChIP can be used to identify tumor-specific transcriptional activity of mutated alleles.

Claim 20proof of principlesupports2021Source 1needs review

This study provides proof of principle that cfChIP can be used to identify tumor-specific transcriptional activity of mutated alleles.

Claim 21proof of principlesupports2021Source 1needs review

This study provides proof of principle that cfChIP can be used to identify tumor-specific transcriptional activity of mutated alleles.

Claim 22transcription observationsupports2021Source 1needs review

In representative NSCLC cell lines, both wild-type EGFR and EGFR-L858R are transcribed, and mRNA is similarly expressed per EGFR copy.

Claim 23transcription observationsupports2021Source 1needs review

In representative NSCLC cell lines, both wild-type EGFR and EGFR-L858R are transcribed, and mRNA is similarly expressed per EGFR copy.

Claim 24transcription observationsupports2021Source 1needs review

In representative NSCLC cell lines, both wild-type EGFR and EGFR-L858R are transcribed, and mRNA is similarly expressed per EGFR copy.

Claim 25transcription observationsupports2021Source 1needs review

In representative NSCLC cell lines, both wild-type EGFR and EGFR-L858R are transcribed, and mRNA is similarly expressed per EGFR copy.

Claim 26transcription observationsupports2021Source 1needs review

In representative NSCLC cell lines, both wild-type EGFR and EGFR-L858R are transcribed, and mRNA is similarly expressed per EGFR copy.

Claim 27transcription observationsupports2021Source 1needs review

In representative NSCLC cell lines, both wild-type EGFR and EGFR-L858R are transcribed, and mRNA is similarly expressed per EGFR copy.

Claim 28transcription observationsupports2021Source 1needs review

In representative NSCLC cell lines, both wild-type EGFR and EGFR-L858R are transcribed, and mRNA is similarly expressed per EGFR copy.

Approval Evidence

1 source3 linked approval claimsfirst-pass slug cell-free-chromatin-immunoprecipitation
cell-free chromatin immunoprecipitation (cfChIP)

Source:

assay capabilitysupports

cfChIP of H3K36me3-associated cfDNA has the potential to delineate whether transcription of a particular gene is occurring in the cells from which its cfDNA originates.

Source:

proof of principlesupports

This study provides proof of principle that cfChIP can be used to identify tumor-specific transcriptional activity of mutated alleles.

Source:

transcription observationsupports

In representative NSCLC cell lines, both wild-type EGFR and EGFR-L858R are transcribed, and mRNA is similarly expressed per EGFR copy.

Source:

Comparisons

Source-backed strengths

The cited study reports that H3K36me3 cfChIP has the potential to delineate whether transcription of a particular gene is occurring in the cells from which its cfDNA originates. In blood plasma from NSCLC patients harboring EGFR-L858R, H3K36me3 cfChIP followed by ddPCR showed significantly higher enrichment of EGFR-L858R fragments than EGFR-WT fragments.

Compared with qRT-PCR

cell-free chromatin immunoprecipitation and qRT-PCR address a similar problem space because they share transcription.

Shared frame: same top-level item type; shared target processes: transcription

Relative tradeoffs: appears more independently replicated.

cell-free chromatin immunoprecipitation and real-time reverse transcription polymerase chain reaction address a similar problem space because they share transcription.

Shared frame: same top-level item type; shared target processes: transcription

cell-free chromatin immunoprecipitation and time-resolved imaging of nucleoid spatial distribution after drug perturbation address a similar problem space because they share transcription.

Shared frame: same top-level item type; shared target processes: transcription

Ranked Citations

  1. 1.
    StructuralSource 1Molecular Oncology2021Claim 1Claim 2Claim 3

    Seeded from load plan for claim c4. Extracted from this source document.